Best FDA-Approved GLP-1 on CarelonRx Formulary (2026): What PA, BE, and QL Mean for You

Published: June 16, 2026 · Last reviewed: June 16, 2026

By The RX Index Editorial Team

The best FDA-approved GLP-1 on CarelonRx formulary depends on one thing: why you qualify. If you’re after weight loss, Zepbound is usually the strongest first medication to ask about — with Wegovy right behind it, and Foundayo if you want a pill. If you have type 2 diabetes, the smarter ask is Ozempic or Mounjaro. We pulled the public CarelonRx Advanced/National 4-Tier Drug List (current as of June 1, 2026) and confirmed every one of these sits at Tier 2 on that list. But here’s the part most people skip right past — a small two-letter note next to the weight-loss drugs that can be the difference between a $25 copay and a four-figure bill. We’ll decode it in plain English.

Quick answer: best FDA-approved GLP-1 on CarelonRx formulary by situation

There is no single “best” GLP-1 for everyone on CarelonRx. The right one is matched to your diagnosis and your specific plan. Weight-loss GLP-1s and diabetes GLP-1s live in different parts of the drug list and follow different rules. Find your row below, then check the one note that decides your real cost.

See the difference in that last column? The diabetes drugs say PA; QL. The weight-loss drugs add a third code: BE. That “BE” can be the whole ballgame — and we’ll explain it right below.

Source: CarelonRx Advanced/National 4-Tier Drug List, current as of June 1, 2026. We read the actual formulary — we didn’t guess. This is one of several CarelonRx lists, so confirm which one your plan uses (we show you how below).

The two-letter code that can decide whether you’re even covered: PA, BE, QL, and ST

On a CarelonRx drug list, PA means prior authorization, QL means quantity limit, ST means step therapy, and BE means benefit exclusion. For weight-loss GLP-1s, the one that trips people up is BE — it means the drug can sit right there on the list and still not be covered by your specific plan. Read these four notes before you get attached to a tier.

Which FDA-approved GLP-1s are on the CarelonRx formulary?

On the CarelonRx Advanced/National list (current as of June 1, 2026), the weight-management section includes Zepbound, Wegovy, Wegovy HD, Wegovy oral, and Foundayo, and the diabetes section includes Ozempic, Mounjaro, Rybelsus, and Trulicity. Weight-loss GLP-1s carry PA; BE; QL. Diabetes GLP-1s carry PA; QL. We read the formulary so you don’t have to open a 150-page PDF on your phone.

Weight-management GLP-1s (anti-obesity section)

Diabetes GLP-1 / GIP-GLP-1s (antidiabetic section)

Which CarelonRx GLP-1 should you ask about first?

Ask about the medication that matches your diagnosis, not the one with the most buzz. Weight loss points to Zepbound or Wegovy; heart disease plus weight points to Wegovy; sleep apnea plus obesity points to Zepbound; type 2 diabetes points to Ozempic or Mounjaro; a strong pill preference points to Foundayo or Wegovy oral. Your qualifying condition is what your doctor writes on the prior authorization — and it’s what gets you approved.

Safety issues to check before asking for any FDA-approved GLP-1

FDA-approved does not mean right for everyone. Before you ask for Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, or Foundayo, talk with your prescriber about whether your medical history changes the risk-versus-benefit picture. These medications carry real warnings in their FDA labeling.

• Thyroid tumors. Injectable GLP-1s (and tirzepatide) carry a boxed warning about a risk of thyroid C-cell tumors seen in animal studies. They should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis (inflammation of the pancreas).
• Gallbladder problems, including gallstones.
• Kidney injury that can come from dehydration if nausea, vomiting, or diarrhea get severe.
• Low blood sugar (hypoglycemia), especially if you also take insulin or a sulfonylurea for diabetes.
• Diabetic retinopathy changes for some people with diabetes on semaglutide.
• Serious digestive side effects — nausea, vomiting, and diarrhea are common, especially as your dose goes up.
• Anesthesia risk. Because these drugs slow how fast your stomach empties, tell any surgeon or anesthesiologist you’re on a GLP-1 before a planned procedure with sedation.
• Pregnancy. These medications aren’t recommended if you’re pregnant or planning to be.

Honest truth: a drug on the list isn’t a drug that’s covered for you

Seeing Zepbound, Wegovy, or Foundayo on the CarelonRx list does not mean your plan will pay for it. CarelonRx says it directly — a listed drug “may not be covered, depending on your plan’s design.” If your employer left weight-loss drugs off the benefit, that Tier 2 listing can still come back as a denial.

We’re telling you this up front because it’s exactly why this page exists. We’re not here to hype a drug and let you find out the hard way at the pharmacy counter. We’re here to help you separate “printed on a list” from “covered for your situation” — so you ask about the right medication, file the right paperwork, and don’t burn three weeks fighting for a drug your plan never intended to cover.

How much will a CarelonRx member actually pay for a GLP-1?

A tier number doesn’t equal a dollar amount, and there isn’t one “price.” There are three different prices people mix up: your insurance copay, the manufacturer’s self-pay price, and the pharmacy list price.

Self-pay prices come from Novo Nordisk and Eli Lilly and are tied to program rules (e.g., LillyDirect’s lower Zepbound prices require refilling within 45 days; some offers exclude Medicare, Medicaid, and certain states). The Wegovy intro pen price of ~$199/month for the first two months ran through June 30, 2026. Verify current pricing before relying on it.

When your CarelonRx plan covers a GLP-1, your copay is almost always the cheapest path — often far below cash. That’s the whole reason to confirm coverage before paying out of pocket. If your plan doesn’t cover it, ask whether a different FDA-approved GLP-1 fits a covered lane, pursue a formulary or benefit exception if your plan offers one, or use a manufacturer self-pay program.

What to do if CarelonRx denies Wegovy, Zepbound, or Ozempic

A denial doesn’t always mean the door is closed. It can mean the benefit is excluded, the paperwork was incomplete, the wrong diagnosis was used, a quantity limit was hit, or the plan wants another drug first. Your first move is to find out which one — the reason on the letter tells you whether to appeal, resubmit, or switch.

For a step-by-step on overturning a “no,” see our guide on how to appeal a GLP-1 denial.

Should you use Ro if you have CarelonRx?

Ro is a strong next step if you want help checking coverage and handling prior authorization for FDA-approved GLP-1s. It’s not a magic workaround for every plan — coverage still depends on your specific benefit. Here’s the honest fit check.

On insurance-driven searches like this one, Ro earns the top spot for a simple reason: it’s built to help you use your insurance, not skip it. For insurance through Ro, coverage currently applies to the Wegovy pen, the Zepbound autoinjector pen, and Ozempic. Separately, Ro offers FDA-approved cash-pay options — Wegovy (pen and pill), Zepbound (pen and KwikPen), and Foundayo — and states its self-pay GLP-1 prices match LillyDirect, NovoCare, and TrumpRx.

Want the deeper breakdown? See our full Ro GLP-1 review and our best FDA-approved GLP-1 providers comparison.

Are compounded GLP-1s on the CarelonRx formulary?

No. This page is about FDA-approved medications on the CarelonRx drug list. Compounded GLP-1 products are not FDA-approved finished drugs, and the FDA does not review them for safety, effectiveness, or quality before they’re sold. Don’t treat them as interchangeable with FDA-approved Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, or Foundayo.

They also don’t appear on the CarelonRx FDA-approved formulary path this page is decoding, and you shouldn’t assume they can be billed through your CarelonRx pharmacy benefit — commercial pharmacy benefits generally don’t cover compounded GLP-1s for that reason.

If your CarelonRx plan completely excludes anti-obesity drugs and an exception doesn’t work, comparing FDA-approved cash-pay options is usually the better next step. See our GLP-1 cost without insurance guide.

On Medicare? Your answer is different (the GLP-1 Bridge)

If you have Medicare, the new GLP-1 Bridge lets eligible Part D members get Wegovy, the Zepbound KwikPen, or Foundayo for weight management at a flat $50 a month — from July 1, 2026 through December 2027 — which is a separate path from commercial CarelonRx coverage. Don’t apply the commercial rules above if you’re on a Medicare plan.

The Bridge is specifically for weight management. If you’re getting a GLP-1 for type 2 diabetes, sleep apnea, heart-risk reduction, or certain liver conditions, that goes through your regular Part D plan — not the Bridge. And the $50 Bridge copay doesn’t count toward your annual out-of-pocket cap. See our Medicare and GLP-1 guide for the full breakdown.

How we built this CarelonRx GLP-1 guide

We pulled the public CarelonRx Advanced/National drug list, lifted out the GLP-1 and incretin-mimetic rows, matched each one to its FDA-approved use, and translated the formulary codes into plain next steps. This is a decision aid, not a coverage guarantee — your plan documents and your prescriber are the final word.

Sources we checked: the CarelonRx Advanced/National 4-Tier Drug List (current as of June 1, 2026) and its official key for PA, BE, QL, and ST; FDA approval information for Wegovy, Zepbound, Ozempic, Mounjaro, Rybelsus, and Foundayo; Novo Nordisk (NovoCare) and Eli Lilly (LillyDirect) self-pay pricing; Ro’s published insurance coverage checker, how-it-works, and pricing pages; and CMS materials on the Medicare GLP-1 Bridge.

We don’t fabricate authors or medical reviewers, and we don’t post star ratings we didn’t earn. This guide is informational and isn’t medical advice. See our editorial standards and decision methodology.

Your action plan

If you have CarelonRx, don’t pick a GLP-1 off a public list. Match the drug to your diagnosis, confirm your own plan’s coverage, then have your prescriber submit the prior authorization with the right paperwork.

1. 1Find your CarelonRx list (Advanced/National, Focused/Essential, Guided/National Direct Plus, or Complete/Traditional).
2. 2Look up Zepbound, Wegovy, Ozempic, Mounjaro, or Foundayo by name.
3. 3Write down the tier and the note — watch for that BE flag.
4. 4Call the number on your card and ask whether your plan excludes weight-loss drugs.
5. 5Ask your prescriber which FDA-approved lane matches your diagnosis — and whether the medication is safe for you.
6. 6Run a free coverage check if you want the answer in writing, and help with the paperwork.
7. 7If you're denied, get the exact reason before you appeal or switch.

Frequently asked questions

See also: Navitus GLP-1 Formulary Guide | Capital Rx GLP-1 Formulary Guide | Prime Therapeutics GLP-1 Formulary Guide